{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:44:32Z","timestamp":1786146272952,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.clbc.2026.07.011","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T08:52:27Z","timestamp":1785401547000},"page":"158-164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor\u2013Positive Early Breast Cancer"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6882-7969","authenticated-orcid":false,"given":"Oliver J.","family":"Nilsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hao S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clbc.2026.07.011_bib0001","article-title":"Trends in the incidence and survival of women with hormone receptor-positive breast cancer from 1990 to 2019: a large population-based analysis","volume":"14","author":"Huang","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.011_bib0002","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"13","key":"10.1016\/j.clbc.2026.07.011_bib0003","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105057","article-title":"Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance","volume":"10","author":"Lobo-Martins","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.clbc.2026.07.011_bib0005","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.breast.2019.05.006","article-title":"Nomogram update based on TAILORx clinical trial results - oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data","volume":"46","author":"Orucevic","year":"2019","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.011_bib0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-024-07346-2","article-title":"Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer","volume":"207","author":"Klein","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.011_bib0007","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1001\/jamaoncol.2021.2132","article-title":"Neoadjuvant endocrine therapy in clinical practice: a review","volume":"7","author":"Sella","year":"2021","journal-title":"JAMA Oncol"},{"issue":"23","key":"10.1016\/j.clbc.2026.07.011_bib0008","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-gene expression assay for therapy guidance in HR+\/HER2- early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clbc.2026.07.011_bib0009","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor\u2013Positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.011_bib0010","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2026.07.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103726","article-title":"Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive\/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature","volume":"75","author":"van Olmen","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.07.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/tbj\/1670410","article-title":"Comparative efficacy of neoadjuvant endocrine therapy, neoadjuvant chemotherapy, and neoadjuvant chemo-endocrine therapy in estrogen receptor\u2013positive breast cancer patients: a meta-analysis","volume":"2025","author":"Yuan","year":"2025","journal-title":"Breast J"},{"key":"10.1016\/j.clbc.2026.07.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104458","article-title":"Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk","volume":"81","author":"M\u00fcller","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2026.07.011_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/tbj\/9976413","article-title":"Efficacy of presurgical short-term endocrine therapy during the waiting period for surgery in postmenopausal hormone receptor-positive breast cancer","volume":"2025","author":"Maeda","year":"2025","journal-title":"Breast J"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105845","article-title":"Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive\/HER2-negative breast cancer patients undergoing preoperative endocrine therapy","volume":"10","author":"G\u00f3mez-Bravo","year":"2025","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.011_bib0016","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.3390\/jcm11113133","article-title":"Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients-a systematic review and meta-analysis","volume":"11","author":"Boszkiewicz","year":"2022","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.011_bib0017","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11912-023-01413-5","article-title":"Aromatase inhibitor musculoskeletal syndrome and bone loss: a review of the current literature","volume":"25","author":"Christensen Holz","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.011_bib0018","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2165\/00003495-198937040-00004","article-title":"Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use","volume":"37","author":"Buckley","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.clbc.2026.07.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1199245","article-title":"The utility of the oncotype DX test for breast cancer patients in an Australian multidisciplinary setting","volume":"2022","author":"Choi","year":"2022","journal-title":"Breast J"},{"issue":"11","key":"10.1016\/j.clbc.2026.07.011_bib0020","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.3390\/cancers13112538","article-title":"The present and future of neoadjuvant endocrine therapy for breast cancer treatment","volume":"13","author":"Mart\u00ed","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.011_bib0021","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/curroncol29040179","article-title":"The clinical impact of neoadjuvant endocrine treatment on luminal-like breast cancers and its prognostic significance: results from a single-institution prospective cohort study","volume":"29","author":"Mart\u00ed","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2026.07.011_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104416","article-title":"Side-effects in women treated with adjuvant endocrine therapy for breast cancer","volume":"80","author":"Rademaker","year":"2025","journal-title":"Breast"},{"issue":"10503","key":"10.1016\/j.clbc.2026.07.011_bib0023","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","author":"Braybrooke","year":"2025","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.clbc.2026.07.011_bib0024","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clbc.2026.07.011_bib0025","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clbc.2026.07.011_bib0026","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clbc.2026.07.011_bib0027","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clbc.2023.03.009","article-title":"Ovarian function suppression in premenopausal women with concurrent endocrine therapy use","volume":"23","author":"Fleege","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2026.07.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105823","article-title":"Short-duration preoperative endocrine therapy alters molecular profiles to predict favourable outcome in ER+\/HER2+ early breast cancer: a POETIC translational study","volume":"118","author":"Sirv\u00e9n","year":"2025","journal-title":"eBioMedicine"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.011_bib0029","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40001-023-01618-1","article-title":"ER-positive and BRCA2-mutated breast cancer: a literature review","volume":"29","author":"Li","year":"2024","journal-title":"Eur J Med Res"},{"issue":"5","key":"10.1016\/j.clbc.2026.07.011_bib0030","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/his.13007","article-title":"Intratumoral heterogeneity of Ki67 expression in early breast cancers exceeds variability between individual tumours","volume":"69","author":"Focke","year":"2016","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.clbc.2026.07.011_bib0031","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.pathol.2019.08.004","article-title":"Invasive lobular carcinoma of the breast: assessment of proliferative activity using automated Ki-67 immunostaining","volume":"51","author":"Dessauvagie","year":"2019","journal-title":"Pathology"},{"key":"10.1016\/j.clbc.2026.07.011_bib0032","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13058-020-01384-6","article-title":"Invasive lobular carcinoma of the breast: the increasing importance of this special subtype","volume":"23","author":"McCart Reed","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2026.07.011_bib0033","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-023-01626-3","article-title":"Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER\u2009+\u2009breast cancer: further results from the POETIC trial (CRUK\/07\/015)","volume":"25","author":"Bliss","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.clbc.2026.07.011_bib0034","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/his.14555","article-title":"Concordance between core needle biopsy and surgical excision specimens for ki-67 in breast cancer \u2013 a systematic review of the literature","volume":"80","author":"Kalvala","year":"2022","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.clbc.2026.07.011_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13000-022-01196-6","article-title":"Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer","volume":"17","author":"Li","year":"2022","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clbc.2026.07.011_bib0036","doi-asserted-by":"crossref","DOI":"10.1111\/his.70203","article-title":"Effects of short-course preoperative endocrine therapy on tumour morphology and immunohistochemical profile in oestrogen receptor-positive, HER2-negative breast cancer","author":"Grosse","year":"2026","journal-title":"Histopathology"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820926001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:31:14Z","timestamp":1786145474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820926001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1526820926001114"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.011","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Feasibility Assessment of Short-Course Preoperative Endocrine Therapy Using the Ki67 Biomarker in an Australian Cohort of Patients With Estrogen Receptor\u2013Positive Early Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2026.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}